Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications
Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study.
Journal: Antimicrobial agents and chemotherapy
Published: January 26, 2026
Ibuzatrelvir potently reduced viral RNA levels despite a high rate of anti-S seropositivity: a post hoc analysis of serology of the phase 2b study.
Journal: Scientific reports
Published: November 17, 2025
Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: September 30, 2024
A phase III, randomized, controlled noninferiority trial to study the efficacy and safety of imipenem/cilastatin/relebactam (IMI/REL) vs piperacillin/tazobactam (PIP/TAZ) in patients with hospital-acquired bacterial pneumonia (HABP) or ventilator-associated bacterial pneumonia (VABP).
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: June 25, 2024
Pharmacokinetics, Safety, and Tolerability of Imipenem/Cilastatin/Relebactam in Children with Confirmed or Suspected Gram-Negative Bacterial Infections: A Phase 1b, Open-Label, Single-Dose Clinical Trial.
Journal: Journal of clinical pharmacology
Published: April 18, 2023
Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis.
Journal: Open forum infectious diseases
Published: January 24, 2023
Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance.
Journal: JAC-antimicrobial resistance
Published: October 05, 2022
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study).
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 23, 2019
Mycobacterium avium pseudo-outbreak associated with an outpatient bronchoscopy clinic: Lessons for reprocessing.
Journal: Infection control and hospital epidemiology
Published: November 27, 2018
A prospective study of transmission of Multidrug-Resistant Organisms (MDROs) between environmental sites and hospitalized patients-the TransFER study.
Journal: Infection control and hospital epidemiology
Published: November 15, 2018
Enhanced disinfection leads to reduction of microbial contamination and a decrease in patient colonization and infection.
Journal: Infection control and hospital epidemiology
Published: August 01, 2018
Effectiveness of targeted enhanced terminal room disinfection on hospital-wide acquisition and infection with multidrug-resistant organisms and Clostridium difficile: a secondary analysis of a multicentre cluster randomised controlled trial with crossover design (BETR Disinfection).
Journal: The Lancet. Infectious diseases
Published: February 07, 2018
Last Updated: 09/26/2026